Introduction ABCB1 gene polymorphisms are associated with rivaroxaban distribution
changes and adverse reactions but the data are controversial. Aim To evaluate the influence …

Background and Objectives: Genetic data on the pharmacokinetics of rivaroxaban and
identification of factors that affect its biotransformation, distribution, and excretion will allow …

Background The influence of genetic factors on the pharmacokinetics and clinical outcomes
of rivaroxaban in patients with non-valvular atrial fibrillation (NVAF) is poorly understood …

Hemorrhage events occur most frequently in anticoagulant therapy for non‐valvular atrial
fibrillation (NVAF). Rivaroxaban is used widely for routine anticoagulation care. Genetic …

Objective The study of ABCB1 and CYP3A4/3A5 gene polymorphism genes is promising in
terms of their influence on prothrombin time variability, the residual equilibrium …

Introduction Individual variability of rivaroxaban was observed in clinical application. This
study aimed to identify genetic variants associated with the variability of pharmacodynamics …

Objective: This study's objective was to evaluate the effects of pharmacokinetic and
pharmacogenetic factors on major bleeding in patients with ACS and non-valvular AF …

Rivaroxaban is excreted from the body via multiple pathways involving glomerular filtration,
drug‐metabolizing enzymes and transporters. In this study, we aimed to examine the impact …

Abstract Background and Objective Rivaroxaban is a novel oral anticoagulant widely used
for thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF). The present …

Background Investigations into the rivaroxaban response from the perspective of genetic
variation have been relatively recent and wide in scope, whereas there is no consensus on …